Table Of ContentANTIBODIES
VOLUME 2: NOVEL
TECHNOLOGIES AND
THERAPEUTIC USE
ANTIBODIES
VOLUME 2: NOVEL
TECHNOLOGIES AND
THERAPEUTIC USE
Edited by
G. Subramanian
Linleboume, Kent, United Kingdom
Springer Science+Business Media, LLC
Library ofCongress Cataloging-in-Publication Data
Antibodies 1 edited by G. Subramanian.
p. ;cm.
Includes bibliographical references and index.
Contents: v. I. Production and purification --v. 2. Novel technologies and therapeutic use.
(divisible set)
I. Monoclonal antibodies--Synthesis. 2. Monoclonal antibodies--Therapeutic use. 3.
Monoclonal antibodies--Biotechnology. I. Subramanian, G., 1935-
[DNLM: I. Antibodies, Monoclonal--isolation & purification. 2. Antibodies,
Monoclonal--therapeutic use. 3. Biotechnology--methods. 4. Chrornatography--methods.
QW 575.5.A6 A6283 2004]
TP248.65.M65A55 2004
615'.37--dc22
2003069160
ISBN 978-1-4613-4702-6 ISBN 978-1-4419-8877-5 (eBook)
DOI 10.1007/978-1-4419-8877-5
©2004 Springer Science+Business Media New York
Originally published by Kluwer Academic Publishers/Plenum Publishers, New York in 2004
Softcover reprint of the hardcover I SI edition
http://www.wkap.nl/
\0987654321
A C.I.P. record for this book is available from the Library of Congress
All rights reserved
No part of this book may be reproduced, stored in a retrieval system, or transmilled
in any form or by any means, electronic, mechanical, photocopying, microfilming, recording,
or otherwise, without wrinen permission from the Publisher, with the exception of any
material supplied specifically for the purpose of being entered and executed on a computer
system, for exclusive use by the purchaser of the work ..
Permissions for books published in Europe: permissions@w/uJp.nl
Permissions for books published in the United States of America: pennissions@w/uJp.com
Preface
It is now over one hundred years since von Behring and Kitsato first
concluded experiments that led to the use of passive immunisation,
employing antibodiesraisedinanimalsagainst tetanusanddiphtheriatoxins.
The advancement oftechnology both in manufacturing purity product in a
cost effective way and the clinical research has proved that antibodies are
oneofthemostsuccessfulproductsinbiotechnology.
Monoclonal antibodies account forbetween one-third andone-halfofall
pharmaceutical products in development and human clinical trials. Both the
nature ofmonoclonal antibody therapies and the relatively large size ofthe
monoclonal antibody dictate theproduction requirements, formanyofthese
therapeutics the monoclonal antibody product will be 100 kilogrammes or
more per year.It iswidelyacknowledged that thereiscurrentlyaworldwide
shortage of biomanufacturing capacity, and the active pharmaceutical
ingredient materialrequirements for theseproducts are expectedtoincrease.
Thustheindustry islooking fornew sourcesand extensivestudiesarebeing
carried out not only foralternative technology to meet the needsbut also to
revealthenewtherapeuticapplicationsofantibodies.
This book brings to the forefront current advances in novel technologies
for the manufacturing of monoclonal antibodies and also their extensive
clinical importance. The first four chapters give an overview of the new
technologies and the successful application in the manufacture of
monoclonal antibodies with clinical purity. The next chapters address the
application ofantibodies in cancer therapy and functional genomictherapy.
The last chapter projects the importance ofantibodies and the prospects of
antibody engineeringandtherapyforthefuture.
v
vi Preface
It is my hope that this book will bring together accumulated knowledge
in a way which will promote the advancement ofthe antibody field, which
will continue to grow and develop new antibodies that are useful to society
atlarge.
I gratefully acknowledge the authors for their time and motivation in
preparing their contributions, without which this book would not have been
possible. Ishouldbe mostgrateful for anysuggestions, which couldserveto
improve future editionsofthisbook
Finally I would like to thank Jo Lawrence ofKluwer Academic/Plenum
forherkeeninterestandhelpthroughout thecompletion ofthisbook.
G. Subramanian
Contributors
Jean-PierreAbastado
ImmunoDesignedMolecule(10M)
172rue deCharonne
75011 Paris Cedex 11
France
Adrian AufDer Maur
ESBATechAG
Wagistrasse21
8952 ZUrich-Schlieren
Switzerland
FabriceAuzelle
ImmunoDesignedMolecule(10M)
172rue deCharonne
75011 Paris Cedex 11
France
DavidAzira
DepartmentofRadiationOncology
CRLCVal d'Aurelle-PaulLamarque
F-34298MontpellierCedex5
France
Alcide Barberis
ESBATechAG
Wagistrasse21
8952 ZUrich-Schlieren
Switzerland
vii
V111 Contributors
Jacques Bartholeyns
ImmunoDesignedMolecule(IDM)
172ruedeCharonne
75011ParisCedex II
France
EmmanuelleBonnin
INSERMU255
CentredeRecherchesBiomedicalesdesCordeliers
IS,ruedel'EcoledeMedicine
75270ParisCedex06
France
Egisto Boschetti
CiphergenBiosystems-Biosepra
48,AvenuedesGenottes
F-95800,Cergy
France
AurtHieBoyer
ImmunoDesignedMolecule(IDM)
172ruedeCharonne
75011ParisCedex II
France
Manuela Campiglio
MolecularTargetingUnit
DepartmentofExperimentalOncology
IsitutoNazionaleTumori
Milan
Italy
GabrielleCaravelho
INSERMU542
Paris-SudUniversity
101ruedeTolbiac
7654ParisCedex13
France
Alain Chapel
InstituteofRadioprotectionandNuclearSafety
IRSN/DAHD/SARAM
Fontenay-aux-Roses
France
Contributors ix
OlivierDeas
INSERMU542
Paris-SudUniversity
101ruedeTolbiac
75654 ParisCedex 13
France
X. K.Deng
Meridian Bioscience
3471 River HillsDrive
Cincinnati
OH45244
USA
DimiterS.Dimitrov
LaboratoryofExperimentalandComputationalBiology
Center forCancer Research
NCI-Frederick,NIH
Bldg 469, Room 246
P.O. Box B,MillerDrive
Frederick
MD 21702-1201
USA
Jean-BernardDubois
DepartmentofRadiationOncology
CRLC Val d'Aurelle-PaulLamarque
F-34298 MontpellierCedex 5
France
AntoineDiirrbach
INSERMU542
Paris-SudUniversity
Rue deTolbiac
75654 ParisCedex 13
France
Christian Frisch
MorphoSysAG
Lena-Christ-Strasse48
D-82152Martinsried/P1anegg
Germany
x Contributors
FrancoisHirsch
INSERMU542
Paris-SudUniversity
101 ruedeTolbiac
75654ParisCedex13
France
SylvieJacod
ImmunoDesignedMolecule(10M)
172ruedeCharonne
75011ParisCedex11
France
ChristelLarbouret
ImmunociblagodesTumeursetIngenieriedesAnticorps
EMI-0227INSERM,UniversiteMontpellier1
CRLCVald'Aurelle-PaulLamarque
F-34298MontpellierCedex5
France
PeterLichtlen
ESBATechAG
Wagistrasse21
8952ZUrich-Schlieren
Switzerland
Delphine Loirat
ImmunoDesignedMolecule(10M)
172ruedeCharonne
75011ParisCedex11
France
AndresMcAllister
ImmunoDesignedMolecule(10M)
172ruedeCharonne
75011ParisCedex11
France
SylvieMenard
MolecularTargetingUnit
DepartmentofExperimentalOncology
IsitutoNazionaleTumori
Milan
Italy
Contributors Xl
K. JohnMorrowJr.
MeridianBioscience
3471 RiverHillsDrive
Cincinnati
OH45244
USA
MaximeMoulard
BioCytex
140Chemindel'Annee d'Afrique
13010Marseille
France
RalfOstendorp
MorphoSysAG
Lena-Christ-Strasse48
D-82152Martinsried/Planegg
Germany
MahmutOzashin
DepartmentofRadiationOncology
CentreHospitalierUniversitaireVaudois
CH 1011 Lausanne
Switzerland
AndrePelegrtn
ImmunociblagodesTumeursetIngenieriedesAnticorps
EMI-0227INSERM, UniversiteMontpellier1
CRLCVald'Aurelle-PaulLamarque
F-34298MontpellierCedex5
France
SereneUaM. Pupa
MolecularTargetingUnit
DepartmentofExperimentalOncology
IsitutoNazionaleTumori
Milan
Italy
DidierPrigent
ImmunoDesignedMolecule(10M)
172ruedeCharonne
75011 ParisCedex11
France
